IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$472.35 USD
+3.17 (0.68%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$472.35 USD
+3.17 (0.68%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
IDEXX Laboratories (IDXX) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q2.
Idexx Laboratories (IDXX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 4.24% and 1.01%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can CAG Growth Continue to Aid IDEXX (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
MASI or STE: Which Is a Better Investment Option Right Now?
by Zacks Equity Research
Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks
by Zacks Equity Research
The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.
IDEXX Laboratories Global Growth Solid on Catalyst Uptake
by Zacks Equity Research
IDEXX (IDXX) steadily demonstrates strong organic growth, driven by solid sales at the Companion Animal Group (CAG) business, fueled by a firm global Catalyst uptake.
Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is IDEXX Laboratories, Inc. (IDXX) Outperforming Other Medical Stocks This Year?
BSX or BAX: Which is a Better Pick for Your Portfolio Now?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Why You Should Add IDEXX (IDXX) Stock to Your Portfolio?
by Zacks Equity Research
IDEXX's (IDXX) stellar performance is primarily driven by robust sales at the CAG (Companion Animal Group) business.
IDEXX Laboratories (IDXX) Up 6.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
IDEXX Laboratories (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Time to Focus on IDEXX Laboratories (IDXX) for Strong Earnings Growth Potential
by Zacks Equity Research
IDEXX Laboratories (IDXX) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG
by Zacks Equity Research
Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
IDEXX Laboratories, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for IDXX for clues.
IDEXX Laboratories (IDXX) Earnings, Revenues Rise in Q1
by Zacks Equity Research
IDEXX (IDXX) rides on strength in CAG business in Q1. A raised EPS guidance buoys optimism.
Zacks.com highlights: Louisiana-Pacific, IDEXX Laboratories, SolarEdge Technologies, Curtiss-Wright and Autohome
by Zacks Equity Research
Zacks.com highlights: Louisiana-Pacific, IDEXX Laboratories, SolarEdge Technologies, Curtiss-Wright and Autohome
IDEXX Laboratories (IDXX) Beats on Q1 Revenues, View Upbeat
by Zacks Equity Research
IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q1.
Invest in These 5 Low Leverage Stocks to Earn Steady Returns
by Zacks Equity Research
With the Q1 earnings season in full swing right now, investors should target low-leveraged stocks exhibiting solid earnings growth.
Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) might repeat its gain streak in CAG for Q1, earlier driven by strong double-digit growth in reference labs and consumables plus a high-single-digit rise in rapid assay sales.
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
The Zacks Analyst Blog Highlights: Seagate Technology, Micron Technology, IDEXX Laboratories, Kohl's and Motorola Solutions
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Seagate Technology, Micron Technology, IDEXX Laboratories, Kohl's and Motorola Solutions
5 Top-Performing S&P 500 Stocks of Q1
by Tirthankar Chakraborty
We have highlighted five S&P 500 stocks that have dished out double-digit returns in Q1 and remained undisturbed by higher bouts of volatility
Why Should You Add IDEXX (IDXX) Stock to Your Portfolio?
by Zacks Equity Research
IDEXX (IDXX) might gain from the commercial launch of Catalyst SDMA Test in North America. As a result, its point-of-care customers can add SDMA as an essential element to the routine chemistry panel.